The OncoMRD (OncoDxRx’s molecular residual disease) test can capture and monitor tumor signals longitudinally in a patient's blood to determine how well a treatment is working in less than 5 days.

Facing a variety of cancer threats from different directions, OncoDxRx recently launched a new gene-to-drug assay PGA that can provide rapid drug efficacy results to patients with limited treatment options.

OncoDxRx has invented an exclusive liquid biopsy technology, PGA, for guiding drug discovery, development and repurposing, ultimately to create a more effective and safer therapeutic option for lung cancer patients.

With the promise of saving millions of lives, OncoDxRx's OncoMRD is born